Synlogic (SYBX) Projected to Post Quarterly Earnings on Tuesday

Synlogic (NASDAQ:SYBX) is expected to announce its earnings results on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. On average, analysts expect Synlogic to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Synlogic Trading Up 2.9 %

Shares of SYBX opened at $1.24 on Friday. The company has a market cap of $14.44 million, a price-to-earnings ratio of -0.30 and a beta of 0.72. Synlogic has a 1-year low of $1.15 and a 1-year high of $2.04. The company’s fifty day simple moving average is $1.38 and its 200 day simple moving average is $1.42.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.